scholarly journals Effect of withdrawing long-term CPAP therapy on the course of obstructive sleep apnea

2021 ◽  
Vol 26 (2S) ◽  
pp. 4314
Author(s):  
M. V. Agaltsov ◽  
O. M. Drapkina

Aim. To assess the effect of withdrawing long-term (12 months) CPAP therapy on the course of obstructive sleep apnea (OSA) in patients with moderate to severe disease.Material and methods. The study included 40 patients with moderate to severe OSA and paroxysmal atrial fibrillation (AF) after surgical treatment. The mean age of the subjects was 59,3+8,2 years. In addition, 55% of patients had obesity. All patients were started on CPAP therapy. After 12 months, CPAP therapy was canceled in the patients who completed the study. Additional cardiorespiratory sleep monitoring was performed 1-2 days after the withdrawal of treatment to assess the severity of sleep-related breathing disorders.Results. Cancellation of CPAP therapy in all observed cases led to an immediate relapse of OSA. Although the mean value of the apnea/hypopnea index (AHI) decreased from 24 episodes per hour [20; 34] before treatment up to 21 episodes per hour [13; 27] after 12-month CPAP therapy, there was no significant difference before and after therapy. In addition, the statistical analysis showed a transition from more severe OSA degrees to moderate ones, depending on the initial severity of the disease. Correlation analysis demonstrated significant relationships of the OSA severity, the final AHI value and the minimum oxygen level with the patient’s body weight (before and after therapy) (r=0,396, 0,411 and -0,488; r=0,358, 0,398 and -0,44, respectively, p<0,05).Conclusion. In our study, when the 12-month CPAP therapy was canceled, no complete cure for sleep-related breathing disorders was recorded in any case. OSA recurrence was recorded immediately after discontinuation of CPAP therapy (on days 1-2) and its severity depended on the initial severity of the disease. At present, the continuation of CPAP therapy remains the only way to achieve complete control of OSA as a risk factor for AF.

2018 ◽  
Vol 24 (4) ◽  
pp. 396-405
Author(s):  
M. V. Agaltsov

Oral  appliances  (ОА)  are  one  of  the  leading  methods  of  effective  treatment  of  sleep-related  breathing disorders. Obstructive sleep apnea (OSA) is a widespread disturbance in the general population. It is closely associated with many cardiovascular diseases (hypertension, cardiac arrhythmias, chronic heart failure, ischemic heart disease). Timely detection and treatment of OSA is an important task in the process of reducing the number of cardiac complications. Modern devices for the treatment of OSA are custom-made devices which allow to change the position of the mandible and its extension providing personalized treatment of snoring and sleep apnea. Changing the degree of the mandible extension, the ОА retains the upper respiratory tract in open position and indirectly stimulates the muscles, determining their tone. The effectiveness of the ОА is evaluated by the complete elimination of all respiratory events (snoring, upper airway resistance syndrome, OSA and hypopnea), as well as the influence on the sleep structure and the wakefulness functioning (excessive daytime sleepiness). The effects of ОА on cardiovascular diseases are of great importance, as they showed a decrease in both systolic and diastolic blood pressure, as well as a positive effect on the impaired endothelial function. Among all the treatment options, ОА take the leading positions, only slightly inferior in effectiveness to noninvasive ventilation, so called CPAP therapy. Regarding the long-term adherence to therapy (which is especially important in the cardiovascular prevention) оral appliances exceed CPAP therapy. Thus, the OA therapy is one of the leading therapeutic directions in modern sleep medicine for obstructive sleep-related breathing disorders.


2020 ◽  
Author(s):  
Ourania S Kotsiou ◽  
Dimitra I. Siachpazidou ◽  
Chaido Pastaka ◽  
Eudoxia Gogou ◽  
Maria Kechagia ◽  
...  

Abstract Background: Hypoxia induces the production of adipocyte-derived mediators such as IL-6 in obstructive sleep apnea syndrome (OSAS). Low serum 25-hydroxyvitamin D (25(OH)D) levels have been linked to OSAS susceptibility. No data exist to assess whether there has been a correlation between vitamin D and IL-6 serum levels. The effect of CPAP therapy on IL-6 or 25(OH)D levels has yet to be investigated sufficiently in OSAS. We aimed at determining the serum levels of 25(OH)D and IL-6 in OSAS patients compared to non-apneic controls, investigating a possible correlation between 25(OH)D and IL-6 levels and evaluating the changes in IL-6 and 25(OH)D concentrations after twelve months of CPAP therapy in OSAS patients.Methods: 15 OSAS patients diagnosed by polysomnography and 15 non-apneic controls were included in the study. Serum IL-6 and 25(OH)D levels were measured before and after twelve-month CPAP therapy in the whole population and OSAS group, respectively.Results: IL-6 levels were significantly elevated in the OSAS group than the controls. IL-6 levels were positively correlated with OSAS severity, nocturnal hypoxemia, and body mass index (BMI). No difference was detected in 25(OH)D serum levels between groups. We found no correlation between IL-6 and 25(OH)D serum levels in two groups. No effect on IL-6 or 25(OH)D levels was detect after one year of effective CPAP therapy in OSAS patients.Conclusions: IL-6 levels were correlated with OSAS severity, hypoxemia, and BMI. No correlation between 25(OH)D and IL-6 levels and no effect of long-term CPAP on biomarkers were found in OSAS patients.


SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A170-A170
Author(s):  
Narumol Luekitinun ◽  
Kanlaya Panjapornpon ◽  
Pattharaphong Plurksathaporn ◽  
Rungaroon Tangsrikertikul ◽  
Wanlana Tongkien ◽  
...  

Abstract Introduction The initial phase of continuous positive airway pressure (CPAP) therapy in patients with obstructive sleep apnea (OSA) may affect sleep parameters and PAP compliance. Actigraphy is a validated method using accelerometer to objectively measure sleep parameters in patients with a range of sleep disorders, including OSA, particularly to follow-up after treatment. We compare sleep parameters from actigraphy, sleep log, sleep diary, Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), heart rate and blood pressure in OSA patients before and after CPAP therapy for 1 week. Methods This pilot study have been prospectively performed at Central Chest Institute of Thailand (CCIT) since June to November 2020. Adult OSA patients, diagnosed by ICSD-3 criteria and achieved optimal or good CPAP pressure titration from split-night polysomnography (PSG), were informed and consent to wear actigraphy before and after CPAP therapy each for 1 week. Clinical and sleep parameters were recorded and analyzed using Wilcoxon matched-pair signed-rank and Mann Whitney U test. P-value &lt; 0.05 was considered to have statistical significance. Results All 11 OSA patients participated in this study. Most patients were male (63.6%), hypertension (54.5%) and dyslipidemia (45.4%). Means of age, body mass index (BMI), ESS, PSQI, apnea hypopnea index (AHI), nadir SpO2, and CPAP usage were 45.5 ± 15.9 years, 29.1 ± 5.2 kg/m2, 10.8 ± 3.9, 7.7 ± 2.9, 65.2 ± 37.7 events/h, 82.3 ± 10.8 % and 9.5 ± 3.1 cmH2O, respectively. Comparing before and after 1-week CPAP therapy, an average number of wake bouts ((NWB), 48.4 vs 38 events, p=0.010), ESS (11 vs 9, p=0.035) and PSQI (8 vs 4, p=0.005) were significantly decrease. Additionally, when comparing between poor and good CPAP compliance group, NWB (55.1 vs 36.3 events, p=0.036) and the difference of wake after sleep onset (WASO, 10.5 vs -0.11 min, p=0.035) were significantly decrease. Conclusion OSA patients treated with CPAP for 1-week experienced marked improvement in sleepiness, sleep quality and nighttime awakening. Support (if any):


2015 ◽  
Vol 12 (2) ◽  
pp. 24-30
Author(s):  
Natalya Viktorovna Strueva ◽  
Galina Afanas'evna Melnichenko ◽  
Mikhail Gur'evich Poluektov ◽  
Larisa Viktorovna Savel'eva ◽  
Gulinara Viktorovna Katsya ◽  
...  

The aim of research was to estimate the influence of hormone metabolism and sleep apnea on patients with obesity. 76 patients (37 males and 39 females) with obesity were included in this study. After night polysomnography all patients were divided in two groups comparableby age, sex ratio and BMI. The first group consisted of 41 patients with obstructive sleep apnea syndrome (OSAS), the second (controls) – 35 patients without breath disorders during sleep. OSAS is accompanied by the increase in urinary cortisol during the night, high levels ofbasal insulin, disturbances of hepatic production of IGF-1, dysfunction of the pituitary-gonadal axis. Our results show that sleep-related breathing disorders render markedly and negatively affect on hormonal parameters of patients with obesity. As a reliable difference of basalsecretion of orexin A in obese patients with and without OSAS was not revealed (42,0 [14; 99,5] vs. 18,0 [14,5; 124,5] pg/ml; р=0,9), we were not able to show the existence that the existence of OSAS is followed by any special changes of activity of the orexin system.


2019 ◽  
Vol 9 (3) ◽  
pp. 205-209 ◽  
Author(s):  
Irina Madaeva ◽  
Natalya Semenova ◽  
Erdem Ukhinov ◽  
Nadezhda Kurashova ◽  
Leonid Sholohov ◽  
...  

2021 ◽  
Author(s):  
Meropi Karakioulaki ◽  
Peter Grendelmeier ◽  
Werner Strobel ◽  
Thomas Schmid ◽  
Kathleen Jahn ◽  
...  

Abstract Study Objectives: Obstructive sleep apnea (OSA) might lead to oxidative stress, inflammation and elevated circulating copeptin, proANP and proADM levels. We aimed to evaluate whether the levels of these prohormones are higher in patients with OSA and whether they might change under continuous positive airway pressure (CPAP) therapy, serving as potential proxies for the diagnosis and therapy-response in OSA. Methods: A total of 310 patients with suspicion of OSA were recruited. Screening for OSA was performed using overnight pulse oximetry followed by polygraphy and a venous puncture in the morning. All patients diagnosed with OSA underwent CPAP adaptation. A venous puncture was conducted in the night before CPAP and in the following morning. At 1 and 6 months of treatment, polygraphy was performed, followed by a venous puncture in the morning. In the acquired blood, copeptin, proANP and proADM levels were measured.Results: We analyzed 232 patients with OSA and 30 patients without OSA. Our results indicated that only copeptin levels differed significantly among patients with and without OSA at baseline. In OSA patients, the levels of proADM significantly changed after 1 and 6 months on CPAP therapy, when compared to baseline (p<0.001 and p=0.020). Additionally, proANP levels significantly decreased after 12 hours on CPAP therapy, as compared to baseline levels (p<0.001). Conclusions: Copeptin is significantly associated with the presence of OSA. ProANP levels might serve as a potential proxy for the acute response to non-invasive ventilation (12 hours), while proADM reflects the long-term response (1 and 6 months).


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2444-2444 ◽  
Author(s):  
Radhika Gangaraju ◽  
Krishna M Sundar ◽  
Jihyun Song ◽  
Josef T. Prchal

Abstract There is a high prevalence of obstructive sleep apnea (OSA) in the United States, with one-quarter of adults aged 30 to 70 years having OSA. Most clinicians consider OSA as one of the causes of elevated hemoglobin (Hb) - polycythemia, but this is based on anecdotal evidence and further work up is often not pursued. Chronic intermittent hypoxia associated with OSA can augment hypoxia-inducible factor-2, the principal regulator of erythropoietin, and may increase red cell mass. But there is a paucity of published data evaluating the effects of OSA and treatment with continuous positive airway pressure (CPAP) on hematologic parameters. We conducted a retrospective analysis of 5152 patients evaluated for OSA with polysomnography at the University of Utah Sleep-Wake Center from January 2013 to October 2015. Hematologic, other laboratory and clinical parameters were available for 527 patients prior to and after therapy of OSA with CPAP. OSA severity was defined as mild (apnea hypopnea index (AHI) 5-15 events/hr), moderate (AHI 15-30/hr) or severe (AHI >30/hr). Data on AHI, lowest oxygen saturation (SpO2) and time spent at SpO2 < 89% were obtained from polysomnography. Other evaluated parameters were age, gender, body mass index, CBC prior to starting CPAP; and Hb and hematocrit (Hct) at 3, 6, 12 and 18 month time points during CPAP therapy. Information regarding comorbidities and medication use that could influence red cell mass was also collected. WHO criteria were used to define polycythemia as Hb >18.5 and 16.5 gm/dl in males and females, respectively. This study included 527 patients, 254 females (48.19%) and 273 males (51.8%), who had at least one Hb measurement prior to starting CPAP therapy. Twenty-one (4%) out of 527 patients had polycythemia, of which 12 were on testosterone supplementation or used home oxygen for chronic pulmonary disease. Excluding these 12 patients resulted in a lower prevalence of polycythemia in OSA of 1.7% (9 patients). JAK2 mutational status or erythropoietin levels, however, were not available for all patients. The polycythemic cohort included 6 females and 3 males with a mean age of 56.6 years. The mean AHI was 35.7; 3 patients had mild, 2 moderate, and 4 severe OSA. Common comorbidities included hypertension (n=5), stroke (n=2) and diabetes (n=2). The mean Hb before CPAP therapy was 17.4 gm/dl, which corrected to normal during CPAP usage in 7 but not in 2. In these 2 patients, Hb corrected to normal with CPAP usage, but increased again by 18 months despite continued CPAP use. The mean Hb was lowest after 3 months of CPAP use and gradually increased thereafter (Table 1). Analysis of mean Hb concentration between different OSA severities (mild, moderate and severe) did not show any significant difference (Table 2). However, when analysis was performed using the normal range for the laboratory used, an additional 16 (3%) patients had Hb above the upper limit of normal (15.9 gm/dl for females and 17.8 gm/dl for males). This resulted in a 7% prevalence of polycythemia in OSA. Excluding patients on testosterone or with chronic lung disease, the overall prevalence was 4.5% (24 patients). Seventeen (3.2%) patients had elevated Hct with normal Hb. Here we report the results from a large dataset of OSA patients measuring the prevalence of polycythemia. Our results show that polycythemia is rarely seen in OSA patients, and other potential causes of polycythemia should be evaluated before attributing it to OSA. The degree of OSA severity does not seem to correlate with Hb level. In those rare polycythemic OSA patients, polycythemia is corrected by CPAP therapy in the majority. However, with the revised WHO criteria for diagnosis of polycythemia vera (16 and 16.5 gm/dl for females and males, respectively), we anticipate that more patients with OSA will be considered to have polycythemia. The low prevalence of polycythemia may be attributed to neocytolysis, wherein transition from sustained hypoxia to normoxia leads to overcorrection of polycythemia due to transient expansion of mitochondria-generating reactive oxygen species, with preferential destruction of young red cells made in hypoxia (Song et al, Mol Med, 2015). We are currently investigating whether neocytolysis also occurs in OSA, which however is characterized by chronic, rapid, repetitious cycles of hypoxia and normoxia that may preclude development of polycythemia in a majority of patients. First and second authors listed contributed equally. Disclosures No relevant conflicts of interest to declare.


2020 ◽  
Author(s):  
Laura Rapisarda ◽  
Monica Gagliardi ◽  
Caterina Bombardieri ◽  
Radha Procopio ◽  
Giulio Demonte ◽  
...  

Abstract BackgroundHeadache and sleep-related breathing disorders among patients with sclerosteosis and disease carriers has been little studied. We investigated the neurological and neuroimaging features of patients and gene carriers of a large Italian family with sclerosteosis.Main bodyIn this Italian family with sclerosteosis, genetic tests detected the homozygous mutation p.Gln24X (c.70C>T) of the SOST gene in the proband, and a heterozygous mutation between 9 siblings. Severe hyperostosis of the skull caused chronic headache secondary to intracranial hypertension due to venous hypertension and obstructive sleep apnea syndrome in adult homozygotes. There was transosseous intracranial-extracranial occipital venous drainage which indicated a compensatory mechanism for intracranial venous hypertension, one of the causative factors of increased CSF pressure in sclerosteosis. While mild hyperostosis of the skull was associated with headache and snoring in heterozygotes. ConclusionsHeadache and sleep-related breathing disorders are the most common clinical manifestations among patients with sclerosteosis and disease carriers. Cerebral venous hypertension leading to intracranial hypertension and facial deformities are the causative factors of headache and sleep-related breathing disorders. These data suggest that venous stenting to accommodate cerebral venous drainage could be useful in the treatment of intracranial hypertension, and correction of facial deformities to relieve obstructive sleep apnea may play a role in the treatment of patients with sclerosteosis. The data highlight that it is reasonable to extend neurological evaluation and radiological study to gene carriers.


2009 ◽  
Vol 141 (2) ◽  
pp. 257-263 ◽  
Author(s):  
Sam Robinson ◽  
Michael Chia ◽  
A. Simon Carney ◽  
Sharad Chawla ◽  
Penelope Harris ◽  
...  

OBJECTIVE: To measure long-term quality-of-life (QOL) improvement following contemporary multilevel upper airway reconstruction surgery, compared with continuous positive airway pressure (CPAP) therapy. Secondary aims were to investigate factors determining clinical effectiveness and QOL impact of reported side effects. DESIGN: Cohort study. SUBJECTS AND METHODS: Consecutive, simultaneously treated adult patients with moderate-severe obstructive sleep apnea (OSA) having upper airway surgery (N = 77) or CPAP (N = 89) therapy were studied by questionnaire. Glasgow Benefit Inventory (GBI), change in snoring status and Epworth Sleepiness Scale (ESS), subjective CPAP compliance, and side effects in both groups were measured at mean ± SEM 44.12 ± 5.78 months (3.68 ± 0.48 years) after commencement of therapy. RESULTS: No significant difference was seen between surgical outcomes for GBI, snoring, or ESS and CPAP controls. Multivariate analysis showed reduction in Respiratory Disturbance Index (RDI) predicted postoperative snoring and ESS, but not GBI outcomes. Snoring control and GBI were related to CPAP compliance ( P < 0.001). CPAP side effects (reported in 26%) significantly reduced the QOL benefit of treatment, independent of compliance. Surgical complications (occurring in 44%) did not affect QOL treatment benefit. CONCLUSION: Patients with poor CPAP compliance and/or significant side effects of CPAP therapy (45% of cases in this series) should be evaluated for contemporary upper airway reconstructive surgery.


Sign in / Sign up

Export Citation Format

Share Document